209 results about "Nude mouse" patented technology

The invention discloses a pharmaceutical composition for reversing pancreatic cancer gemcitabine drug resistance and application of the pharmaceutical composition, and belongs to the technical field of biological medicine. The composition comprises a generic FGFR inhibitor delatinib and gemcitabine, the concentration of the delatinib is 25 to 50 mg / kg, and the concentration of the gemcitabine is 20 to 30 mg / kg. By inhibiting an FGFR2 / FGFR3 signal channel and reducing the expression of FGFR protein in drug-resistant cells, the chemosensitivity of gemcitabine is synergistically enhanced, the apoptosis induction rate is increased by more than two times, and the synergic index (CI) is less than 1. In-vitro and nude mouse transplantation tumor experiments prove that the composition can significantly inhibit the proliferation of gemcitabine drug-resistant pancreatic cancer cells. The Gemcitabine drug-resistant pancreatic cancer drug can be used for preparing a drug for treating Gemcitabine drug-resistant pancreatic cancer with high FGFR3 expression, patients are screened through immunohistochemistry or gene sequencing, intravenous injection or oral administration is adopted, dosage forms comprise freeze-dried powder injection, capsules or tablets, and a new strategy is provided for pancreatic cancer drug-resistant treatment.

The invention belongs to the technical field of medicines, and relates to a dimethyl phosphine oxide substituted aniline pyrimidine derivative targeting EGFR mutation, a preparation method and application thereof, and a medicine prepared from the dimethyl phosphine oxide substituted aniline pyrimidine derivative. The invention provides a compound as shown in a formula I. The compounds have outstanding inhibitory activity (at a nanomole level) and selectivity on EGFRT790M / C797S / L858R kinase and EGFRL858R / T790M kinase, have an obvious inhibitory effect on a non-small cell lung cancer cell line, particularly have outstanding selectivity on EGFR mutant cells H1975, and have an obvious inhibitory effect. The compound disclosed by the invention has a remarkable tumor inhibition effect in a nude mouse heterophylloma model and is relatively low in in-vivo toxicity. Therefore, the compound provided by the invention can be used as an epidermal growth factor receptor tyrosine kinase inhibitor to be applied to preparation of anti-lung cancer drugs, and has a good application prospect. And the formula I of the # imgabs0 # is shown in the specification.

The invention relates to the technical field of drugs for treating thyroid cancer, in particular to application of honeysuckle polysaccharide in preparation of drugs for treating thyroid cancer. According to the technical scheme, on the basis of separating and purifying the honeysuckle polysaccharide with relatively good uniformity, the honeysuckle polysaccharide is found to have no toxic effect on normal thyroid follicular cells, but selectively inhibits proliferation of recurrent metastatic papillary thyroid carcinoma cells, and has an inhibiting effect on transplanted tumors of nude mice inoculated with a recurrent metastatic papillary thyroid carcinoma cell line. According to the scheme, the honeysuckle flower polysaccharide is good in homogeneity, the molecular weight is 23 + / -4 kDa, the honeysuckle flower polysaccharide is mainly composed of five monosaccharides, and alpha-(1-> 4)-D-GalpA is mainly connected to form a main chain. The polysaccharide has no toxic effect on normal thyroid cells while effectively inhibiting the cell viability of IHH-4. According to the technical scheme, the technical problem that drugs for treating recurrent metastatic papillary thyroid carcinoma with small side effects and high specificity are lacked in the prior art can be solved, and the drug has an ideal application prospect.

The invention discloses application of an azetidine compound in preparation of a medicine for preventing and treating triple-negative breast cancer, and belongs to the technical field of biological medicine. By adopting an international common triple-negative breast cancer modeling method, the scheme shows that the compound can effectively inhibit the tumor growth state of nude mouse triple-negative breast cancer, inhibit STAT3 705 site tyrosine phosphorylation and induce tumor cells to generate G2-M phase arrest and apoptosis, and has remarkable prevention and treatment effects on triple-negative breast cancer; the compound is expected to become a novel medicine for treating triple-negative breast cancer.

The invention discloses a tissue engineering integrated trachea regeneration construction method based on a frame structure scaffold and application. A multi-tissue-structure integrated gas pipe is constructed based on a 3D printing bioelastomer frame structure support, and the complex structure and physiological functions of a natural gas pipe are highly simulated. The preparation method comprises the following steps: firstly, by utilizing the characteristic that temperature-sensitive hydrogel Pluronic F-127 becomes semi-solid gel at 37 DEG C and is liquefied at a low temperature of 4 DEG C, and by adopting a strategy that the temperature-sensitive hydrogel is sacrificed after occupying, the patterned distribution of chondrocytes and fibroblasts on a two-dimensional plane is realized; secondly, simulating a three-dimensional tubular trachea structure through a 2D-3D (two-dimensional to three-dimensional) rolling assembly strategy, and realizing the ordered regeneration of C-shaped cartilage ring / O-shaped fiber ring alternate distribution and axial strip-shaped fiber bundle triple structures under the skin of the nude mouse. And finally, successfully extracting the airway mucosa epithelium, separating and amplifying enough airway basal cells in vitro, and loading the airway basal cells to the inner wall of the regenerated trachea by utilizing the photo-crosslinking hydrogel, thereby realizing the function simulation of the airway epithelium and enhancing the physiological functionality.

The invention discloses application of annular RNACirc3426 as a diagnostic marker and a therapeutic target of colorectal cancer. Experiments show that the Circ3426 is highly expressed in colorectal cancer cells and patient serum, and prove that the Circ3426 has good stability, and an ROC curve shows that the Circ3426 has good capacity of diagnosing colorectal cancer. Meanwhile, it is found that the molecule can promote migration and invasion ability of colorectal cancer cells, nude mouse subcutaneous tumor formation experiments prove that knock-down Circ3426 inhibits growth of tumors, and it is indicated that the molecule can serve as a treatment target of colorectal cancer. The invention provides a new diagnostic marker and a treatment target for colorectal cancer, and provides a new thought and direction for CRC diagnosis and treatment.

The invention discloses a new application of human YTHDF1, namely an application of a human YTHDF1 gene expression quantity detection reagent in preparation of a prostatic cancer clinical diagnosis reagent. The expression of the human YTHDF1 gene in prostatic cancer tissues and cell lines is increased; after the expression of the YTHDF1 gene is knocked down, the growth of a prostate cancer cell line, the culture of organoids and the growth of transplanted tumors in nude mice are obviously inhibited; according to the present invention, with the application of the RNF7 in the tumor cells, the proliferation of the normal prostate epithelial cells can be promoted by the overexpression, the protein level of the RNF7 in the YTHDF1 knocked-down cells is significantly inhibited, the phenotype of the YTHDF1 knocked-down cells can be rescued by the overexpression of the RNF7, and the sensitivity of the tumor cells to the chemotherapeutic drugs can be promoted by the YTHDF1 knocked-down cells so as to promote the apoptosis; the prostatic cancer can be treated by inhibiting expression drugs of the human YTHDF1 gene, inhibiting expression of the E3 ubiquitin ligase RNF7 gene or screening drugs for degrading the E3 ubiquitin ligase RNF7.

The present invention relates to the technical field of thyroid cancer drugs, and specifically relates to the application of honeysuckle polysaccharide in the preparation of drugs for treating thyroid cancer. Based on the isolation and purification of honeysuckle polysaccharide with good homogeneity, it is found that it has no toxic effect on normal thyroid follicular cells, but selectively inhibits the proliferation of recurrent and metastatic papillary thyroid cancer cells, and has an inhibitory effect on the xenograft tumors of nude mice inoculated with recurrent and metastatic papillary thyroid cancer cell lines. The honeysuckle polysaccharide of this scheme has good homogeneity, a molecular weight of 23 ± 4 kDa, and is mainly composed of five monosaccharides, mainly connected by α-(1→4)-D-GalpA to form the main chain. While the polysaccharide effectively inhibits the cell viability of IHH-4, it has no toxic effect on normal thyroid cells. This technical scheme can solve the technical problem in the prior art of lacking drugs with small side effects and high specificity for treating recurrent and metastatic papillary thyroid cancer, and has an ideal application prospect.

The invention relates to the technical field of biological medicines, and provides application of ADRM1 gene / protein in preparation of a medicine for treating osteosarcoma. When the ADRM1 gene / protein is applied to the preparation of the medicine for treating osteosarcoma, the proliferation, migration and invasion capabilities of tumor cells can be remarkably inhibited, so that the occurrence and development of osteosarcoma are delayed. The expression of the ADRM1 is knocked down through an shRNA intervention technology, the mRNA and protein level of the ADRM1 in 143b and U2OS osteosarcoma cell lines can be remarkably reduced, the short-term proliferative activity and the long-term clone forming ability of the ADRM1 are further inhibited, and the migration and invasion characteristics of cells are effectively weakened. The growth of a tumor body formed after a nude mouse is inoculated with 143b osteosarcoma cells knocking down ADRM1 is obviously slowed down, and the expression of a cell proliferation marker KI-67 in the tumor body is reduced, which indicates that the ADRM1 gene / protein also plays a key regulation role in the in-vivo growth process of osteosarcoma.

The invention discloses an application of homocapsaicin II in preparation of an anti-tumor drug, the homocapsaicin II is used in the anti-tumor drug independently or in combination with 5-fluorouracil or in combination with oxaliplatin, and when the homocapsaicin II is used in preparation of an anti-colorectal cancer drug, the drug concentration is 20-200 [mu] M. It is found that high capsaicin II can inhibit growth of intestinal cancer cells in vivo and in vitro, and nude mice have good tolerance to the natural compound. When the compound is used together with a first-line chemotherapeutic drug 5-fluorouracil, the drug concentration of the 5-fluorouracil can be remarkably reduced while the same treatment effect is achieved, a synergistic cancer inhibition effect is achieved, and a new research and development approach is found for anti-colorectal cancer drugs.

The invention relates to an application of Avasimibe in preparation of a medicine for treating nasopharynx cancer or oral cancer, and belongs to the field of tumor targeted therapy. An in-vitro cell experiment and an in-vivo animal model experiment verify the anti-tumor effect of the compound. Experiments show that Avasimibe can significantly inhibit the activity, proliferation ability, healing ability and cloning ability of nasopharynx cancer cells and oral cancer cells, can regulate cell cycle arrest in a dose-dependent manner, and induces cell apoptosis. In vivo experiments, the tumor volume of nude mice in an Avasimibe treatment group is remarkably reduced, serum cholesterol is remarkably reduced, and serum biochemical analysis shows that compared with a control group, the Avasimibe treatment group has no statistical difference in indexes such as aspartate transaminase (AST) / glutamic-pyruvic transaminase (ALT) and creatinine (Cr). The invention provides a new indication for resisting nasopharynx cancer and oral cancer for the existing compound Avassimibe, has the clinical advantages of low toxicity and capability of overcoming drug resistance, and provides a new treatment choice for patients with nasopharynx cancer and oral cancer.

The application discloses a five-heterocycle compound, a preparation method and application thereof. Specifically disclosed are a compound as shown in formula I, a pharmaceutically acceptable salt or solvate thereof, a composition containing the compound, and a pharmaceutical use of the compound for preparing a drug for treating a disease or disorder related to the mechanism of action of KRAS G12C mutant protein. The five-heterocycle compound in the application has the activity of inhibiting the proliferation of Ba / F3 KRAS-G12C cells, NCI-H358 cells and MIA PaCa-2 cells expressing KRAS G12C mutant protein, and has a good inhibitory effect on the growth of a subcutaneous transplanted tumor of a NCI-H358 nude mouse.

The invention provides an application of an ANGPT2 monoclonal antibody in preparation of a medicine for treating non-small cell lung cancer of a subject subjected to heavy ion treatment. Research results show that the promotion effect of the combined treatment of the nevapsumab and the heavy ion irradiation on ANGPT2 overexpression A549 cell cycle arrest and cell apoptosis rate and the inhibition effect on cell invasion, migration and clone forming ability are obviously better than those of the single treatment of the nevapsumab and the heavy ion irradiation. In a nude mouse transplantation tumor model, the inhibition effect of the combined treatment on the growth of ANGPT2 overexpression A549 cell transplantation tumor is more obvious than that of the single treatment of nevapsumab and heavy ion irradiation, and the negative influence on the physiological state of a host is smaller. A new strategy is provided for clinical treatment of the non-small cell lung cancer, and it is indicated that combined application of heavy ion treatment and ANGPT2 monoclonal antibody is expected to improve the treatment effect, prolong the lifetime of a patient and reduce treatment-related side effects, so that the life quality of the patient is remarkably improved.

A primer pair, method, and use for rapidly identifying newborn nude mice. On the basis that a deletion mutation occurs in the base G at position 337 of a coding region of the Foxn1 gene in nude mice, a primer pair introducing an enzyme digestion site is designed according to sequence characteristics. Using the genome of a mouse to be tested as a template, the Foxn1 gene is amplified according to a PCR-RFLP method. The PCR product is then digested with a SmaI restriction endonuclease, and the digested product is genotyped by agarose gel electrophoresis. In addition, a reaction system that can be combined with lateral flow technology is screened, thereby achieving instant detection of the newborn nude mice. The method has the characteristics of simple operation, short time consumption, low cost, instant detection, etc.

The invention discloses application of lncRNASEH1-AS1 as a target in preparation of a medicine for treating lung squamous cell carcinoma, and belongs to the technical field of biological medicine. The invention finds that the expression of the lncRNASEH1-AS1 in tissues, plasma and cell lines of a lung squamous cell carcinoma patient is higher than that of a control group of the lung squamous cell carcinoma patient. The lncRNASEH1-AS1 has clinical correlation with the tumor diameter of a lung squamous cell carcinoma patient. The results of CCK-8, clone formation, Transwell migration and invasion experiments show that after the lncRNASEH1-AS1 and the MCM7 are knocked down, the proliferation, migration and invasion ability of the lung squamous cell carcinoma cells is weakened, and after the lncRNASEH1-AS1 is over-expressed, the inhibition of the MCM7 on the proliferation, migration and invasion ability of the lung squamous cell carcinoma cells can be reversely knocked down. The result of a nude mouse subcutaneous tumor formation experiment shows that the tumor formation capability of the LUSC cells which stably knock down the lncRNASEH1-AS1 is weakened.

The application discloses application of Ophisaurus apodus in preparation of a drug for reversing drug resistance of gastric cancer and belongs to the technical field of medicines. The application can reduce tumor volume and size, promote drug resistance cell apoptosis, and reverse the chemotherapeutic drug resistance of a nude mouse with gastric cancer by jointly using Ophisaurus apodus in different parts of the body and cisplatin, by down-regulating P-gp, MRP1 and Bcl-2 protein expression, and by up-regulating Bax protein expression. The effect of the tail + cisplatin group is the most significant.

The invention discloses sargassum fusiforme polysaccharide with a barrier repairing function and a preparation method and application thereof. The molecular weight of the sargassum fusiforme polysaccharide is 39-278 kDa, the total sugar content is 50-55 wt%, and the uronic acid content is 29-35 wt%. The preparation method comprises the following steps: (1) hot water extraction: mixing sargassum fusiforme powder with water, and performing hot water extraction, evaporation concentration, alcohol precipitation and freeze-drying; (2) ultrasonic treatment: mixing with water, and performing ultrasonic degradation; and (3) UV / H2O2 degradation: mixing with a H2O2 solution, carrying out UV degradation, removing H2O2, dialyzing, evaporating and concentrating, and freeze-drying to obtain the product. The sargassum fusiforme polysaccharide prepared by the invention can significantly improve the content and expression of filagarisin (FLG) of nude mice and HaCaT cells after UVB irradiation, reduces the percutaneous moisture loss value (TEWL) in nude mice, has a significant skin barrier repair function, and can be used for development and utilization of functional foods and skin care products.

The invention discloses an application of a disulfide bond isomerase single-domain antibody in preparation of a product for treating and / or preventing leukemia, the disulfide bond isomerase single-domain antibody comprises a variable region, and the variable region comprises CDR1, CDR2 and CDR3; the amino acid sequences of CDR1-CDR3 of the disulfide bond isomerase single-domain antibody are sequentially as shown in SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, and the CDR1-CDR3 are defined according to an IMGT definition scheme. The single-domain antibody provided by the invention can be used for remarkably inhibiting the growth of subcutaneous transplanted tumors of Ba / F3BCR-ABLT315I cells in nude mice, and has an obvious inhibiting effect on drug-resistant chronic granulocytic leukemia.

The present application relates to in situ model modeling method, especially for a kind of non-invasive cervical cancer in situ model modeling method of mouse, including selecting several 8 weeks old BALB / c-nude mouse, all mice are divided into non-invasive group and operation group, the age, weight of two groups of mice are compared, and there is no statistically significant difference;Non-invasive group is widened with the cotton stick of diameter 3mm and wipes dry vagina, the tumor block with luciferase fluorescence is immersed in modified hydrogel, after heating and making modified hydrogel solidification, the tissue glue mixed with hard gypsum in modified hydrogel is dropped on the surface of modified hydrogel and quickly inserted into vagina, when there is obstruction, stop deepening, pause 30s and wait for tissue glue to be completely dry, when tumor block is fixed in cervix, it is modeling completion;Operation group first opens abdominal cavity, and tumor tissue of same size is sutured on cervix.This kind of non-invasive cervical cancer in situ model modeling method of mouse, using non-invasive method to replace operation method to establish non-invasive cervical cancer in situ model, can reduce the pain of mouse, reduce experimental difficulty.

The invention belongs to the technical field of biological medicine, and relates to a kidney cancer axitinib drug-resistant cell model and a construction method and application thereof. The technical problems that in the prior art, a kidney cancer axitinib drug resistance mechanism is not clear, and a drug resistance target of the mechanism and a cell model of a molecular mechanism are lacked for research are solved. The invention provides a construction method of a kidney cancer axitinib drug-resistant cell model. The construction method comprises the following steps: constructing a nude mouse subcutaneous tumor-bearing model by using a kidney cancer cell line; when a subcutaneous tumor of a nude mouse reaches a target volume, after axitinib gavage treatment is performed on the nude mouse, first-generation drug-resistant kidney cancer cells are obtained through separation; shearing the tumor blocks into tumor blocks, inoculating the tumor blocks to the armpits of nude mice, and repeating the steps of gavage, separation and inoculation to respectively obtain second-generation and third-generation drug-resistant kidney cancer cells; and cutting the third-generation drug-resistant kidney cancer cells into pieces, digesting and culturing to obtain the kidney cancer axitinib drug-resistant cell model. The constructed kidney cancer axitinib drug-resistant cell model is applied to research of a kidney cancer cell targeted therapy drug-resistant mechanism and screening or preparation of kidney cancer targeted drugs.

The application discloses application of Rhamnus hemisphaerica in preparation of anti-pancreatic cancer drugs, wherein the Rhamnus hemisphaerica is dry root of Semiliquidam bar cathayensis Chang of Rhamnaceae. Researches show that the Rhamnus hemisphaerica can inhibit proliferation, invasion and migration of pancreatic cancer cells Pan-1, promote apoptosis, has anti-pancreatic cancer activity, can significantly inhibit growth of tumor of a subcutaneous nude mouse xenograft model of pancreatic cancer cells Panc-1, significantly inhibit expression of a tumor proliferation related factor Ki67, and has no obvious toxic side effect on mice. The application firstly discloses that the Rhamnus hemisphaerica has obvious anti-pancreatic cancer activity, can be used for preparation of anti-pancreatic cancer drugs, provides a new efficient and safe drug source for treatment of pancreatic cancer, and provides a basis for further development and utilization of the Rhamnus hemisphaerica.

The invention provides an application of 2-indolecarboxylic acid in preparation of a tumor targeted therapy drug. Through computer-aided drug design and molecular docking optimization, 2-indolecarboxylic acid shows high binding energy to an HER2 kinase structural domain. In HER2 positive NCI-N87 gastric cancer cells, the 2-indolecarboxylic acid significantly inhibits cell proliferation and induces G0 / G1 phase arrest and apoptosis. The mechanism research shows that the 2-indoleformic acid can play a role by regulating and controlling the HER2 / Akt / beta-catenin pathway (Western blot verification). In an NCI-N87 cell tumor-bearing nude mouse model, 2-indolecarboxylic acid (15 mg / kg) significantly inhibits tumor growth, and does not cause obvious weight loss or organ toxicity. Immunohistochemical analysis shows that the positive rate of a tumor tissue proliferation marker Ki-67 in a treatment group is remarkably reduced, and apoptosis detection shows that the proportion of TUNEL positive cells is remarkably increased, which indicates that 2-indolecarboxylic acid inhibits tumor cell proliferation and promotes apoptosis at the same time. The invention provides a lead compound with clinical transformation potential for HER2 targeted therapy.

The present invention belongs to the field of biomedical technologies, and particularly relates to the application of pyruvate in the preparation of a drug for enhancing the efficacy of lung cancer chemotherapy. The present invention provides a novel drug for treating lung cancer, namely Compound I obtained by structurally modifying sodium pyruvate. Experimental results show that this compound can significantly inhibit the proliferation of lung cancer cells A549 in mice, and at the same time has an inhibitory effect on the growth of human lung cancer A549 cell xenografts in nude mice, expanding the therapeutic potential of existing drugs and providing new treatment options for lung cancer patients. Its high efficiency in treating lung cancer is of great significance in improving the treatment effect and reducing the burden on patients.

The present invention relates to the field of biomedicine technology, and specifically discloses an anti-tumor antigen BAP31 monoclonal antibody, a Cy5-BAP31 directly labeled monoclonal antibody and its application. The monoclonal antibody includes a heavy chain variable region and a light chain variable region. The nucleotide sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.1, and its amino acid sequence is shown in SEQ ID NO.3. The nucleotide sequence of the light chain variable region of the monoclonal antibody is shown in SEQ ID NO.2, and its amino acid sequence is shown in SEQ ID NO.4. The anti-BAP31 monoclonal antibody provided by the present invention can specifically recognize the BAP31 molecule, inhibit the subcutaneous tumor formation ability and in vivo metastasis ability of liver cancer cells, and significantly prolong the survival of tumor-bearing nude mice.

The invention discloses DUSP23 targeted siRNA and application thereof, and belongs to the technical field of molecular biotechnology and genetic engineering. By researching the expression level of DUSP23 in liver cancer tissues, an action target of the DUSP23 gene is provided for treatment of liver cancer; the invention provides siRNA for inhibiting expression of a human DUSP23 gene and protein and application of the siRNA. The nucleotide sequence of the siRNA is shown as SEQ ID NO.5-SEQ ID NO.6. The invention further provides a preparation method of the siRNA. By transfecting the siRNA in a hepatoma carcinoma cell line, DUSP23 gene and protein expression can be regulated and interfered, cell proliferation and migration ability can be inhibited, cell cycle G0 / G1 phase arrest and cell apoptosis can be induced, and the siRNA has remarkable tumor inhibition activity on transplanted tumor in nude mice of hepatoma carcinoma cells.

The invention discloses a novel application of total glucosides of paeony in preparation of a medicine for treating triple negative breast cancer. In-vitro and in-vivo experiments prove that the total glucosides of paeony can remarkably inhibit proliferation, migration and invasion of triple negative breast cancer cells (MDA-MB-231 and MDA-MB-468), reverse an epithelial-mesenchymal transition process and induce cell apoptosis by inducing mitochondrial injury, inhibiting oxidative phosphorylation and activating a mitochondrial apoptosis pathway. In an MDA-MB-231 cell xenotransplantation tumor nude mouse model, the total glucosides of paeony can effectively inhibit tumor growth. Therefore, the total glucosides of paeony can be used for preparing the medicine for treating the triple negative breast cancer, and a new treatment choice is provided for clinic.

The application relates to the field of biological medicine, and provides application of ADRM1 gene / protein in preparation of a drug for treating osteosarcoma. The ADRM1 gene / protein is applied to preparation of the drug for treating osteosarcoma, can significantly inhibit proliferation, migration and invasion ability of tumor cells, and thus delays occurrence and development of the osteosarcoma. By shRNA intervention technology, the expression of ADRM1 is knocked down, the mRNA and protein levels of ADRM1 in 143b and U2OS osteosarcoma cell lines are significantly reduced, short-term proliferation activity and long-term clone formation ability are inhibited, and migration and invasion characteristics of the cells are effectively weakened. After 143b osteosarcoma cells with the knocked-down ADRM1 are inoculated into nude mice, the growth of the tumor formed by the cells is obviously slowed down, and the expression of a cell proliferation marker KI-67 in the tumor is down-regulated, indicating that the ADRM1 gene / protein also plays a key regulation role in the in-vivo growth process of the osteosarcoma.

The invention discloses a drug delivery system containing loaded adriamycin as well as a preparation method and application of the drug delivery system. The drug delivery system comprises poly (beta-amino ester) coupled with adriamycin, wherein the surface of the poly (beta-amino ester) is coated with dextran sulfate, and the poly (beta-amino ester) takes a fourth-generation lysine dendritic molecule Lys-G4 as a core. The drug delivery system has a pH-dependent drug release characteristic, has remarkable toxicity to C6 and U87MG glioma cells, has the capabilities of inducing apoptosis, inhibiting migration and targeting subcellular localization, and can effectively penetrate through a blood-brain barrier model and 3D tumor spheres. The delivery system is compounded with PLA-PEG-PLA thermosensitive hydrogel, and the thermosensitive hydrogel with a drug storage function is successfully constructed. Good tumor inhibition effect and biocompatibility are shown in nude mouse subcutaneous and in-situ glioma models. The invention not only provides a new strategy for overcoming the blood brain barrier, but also can effectively reduce the systemic toxicity, and opens up a new research thought and method for glioma treatment.

The invention belongs to the technical field of nanotechnology, and relates to a preparation method and application of ferrocene-loaded electroactive mesoporous silica composite nanoparticles. Specifically, MSNs are constructed as a template, elemental platinum is subjected to in-situ reduction and loaded on the MSNs, and ferrocene is used as an electroactive group, so that the Fc / Pt-coated MSNs (FPMSN) nanoparticles with electroactivity are successfully synthesized. A HepG2 tumor-bearing nude mouse model is constructed, FPMSNs combined electrodynamic therapy antibody internal tumor effect research is carried out, and tumor growth is proved to be effectively inhibited by FPMSNs combined electrodynamic therapy through weight and tumor volume measurement of tumor-bearing nude mice in different treatment groups. The obvious effectiveness and good biological safety of the FPMSNs electrodynamic therapy provide a new way for developing a new cancer treatment method.

The invention discloses an application of a circRNA marker in diagnosis and treatment of colorectal cancer, the expression level of a circular RNA gene hsacirc0066801 in samples of patients with colorectal cancer and tumor cells is obviously improved, and the overexpression of the circular RNA hsacirc0066801 can obviously promote the proliferation, migration and invasion of the colorectal cancer cells. Meanwhile, knock-down of the hsacirc0066801 can significantly inhibit proliferation, migration and invasion of colorectal cancer cells, in addition, nude mouse tumor formation experiments prove that the tumor volume is significantly increased after overexpression of the hsacirc0066801, and is reduced after knock-down of the hsacirc0066801. Therefore, the hsacirc0066801 can be used as a potential molecular marker and is used as a target spot for clinical diagnosis and treatment of the colorectal cancer.